SUMMARY A report of 20 cases of gout considered to be secondary to chronic renal disease is presented. Studies of renal function and of uric acid metabolism were carried out in 16 patients. The daily production of urate remained within normal limits in the face of progressive renal dysfunction. Renal excretion of uric acid was decreased to a mean of 35.5% of the turnover. The
Patients and methods
Sixteen patients participating in metabolic studies were maintained on a diet essentially free of purines for 5 days before as well as during the study. All drugs were discontinued 2 weeks prior to the study. Plasma and urinary uric acid was determined by an enzymatic spectrophotometric method.8 On the sixth day 14C-2-uric acid was injected intravenously in a dose of 20 to 40 ,uCi. Uric acid was isolated from the urine and purified as described elsewhere.9 Radioassay of 14C was done either in a vibrating reed electrometer after wet oxidation of uric acid in a vacuum combustion line9 or in a liquid scintillation spectrophotometer by the following technique: Preweighed amounts of uric acid were dissolved in 2 ml hyamine hydroxide, then mixed with 18 ml of a mixture of PPO (2,5-diphenyloxazole), 3 g, POPOP (1, 4-bis-2-(5-phenyloxazolyl)-benzene), 100 mg, and toluene, 1000 ml. In this system 14C-toluene counted with an efficiency of approximately 70%. All A 66-year-old woman presented with acute arthritis of the left first metatarsophalangeal joint, extending to the dorsum of the foot. Aspiration yielded 0 5 ml of milky fluid which under polarised light contained negatively birefringent crystals. Plasma urate concentration was 0 56 mmol/l and serum urea nitrogen was 14 6 mmol/l. Sixteen years previously, the patient underwent removal of 3 hyperplastic parathyroid adenomas, one of them weighing close to 30 g. At the time of surgery multiple bilateral interstitial renal calcifications were present. Prior to surgery serum calcium had ranged between 3 52 and 3 -90 mmol/l and serum phosphorous between 0 61 and 0 90 mmol/l.
CASE 1 8
A 56-year-old woman was seen in the outpatient clinic for acute arthritis of the right ankle. Swelling and redness were present. 3 ml of inflammatory fluid was aspirated from the subtalar joint. Intracellular negatively birefringent crystals were present. The patient had experienced 5 similar episodes during the preceding 3 years. Mild hypertension had been noted off and on for 5 years, and during the past year she had taken hydrochlorothiazide.
Laboratory tests revealed a plasma urate of 0'85 mmol/l while on the diuretic and 0-81 mmol/l off medication. Serum calcium was 3*15 and 3*10 mmol/l and serum inorganic phosphorous 0 87 and 0-81 mmol/l. Parathyroid hormone level was elevated at 1 9 ng/ml compared to an upper normal value of 12 ng/ml. Serum urea nitrogen was 17-1 mmol/l. The urine contained 3 -27 mmol of uric acid in a 24-hour period, and urate clearance was 2 -8 ml/min. The patient refused surgical exploration of the neck for primary hyperparathyroidism. CASE 
19
A 64-year-old woman presented with acute inflammation of the metatarsophalangeal and interphalangeal joints of the left big toe. Synovial analysis showed numerous negatively birefringent crystals mainly inside polymorphonuclear leucocytes. An inferior vena cavagram showed displacement and encroachment upon the inferior vena cava by a retroperitoneal process. Since the BUN continued to rise it was felt that the indwelling ureteral catheters did not provide adequate drainage. Surgical exploration showed the ureters to be embedded in a thick fibrous tissue, which was partly excised. To ensure adequate drainage bilateral nephrostomies were performed. However, the BUN continued to rise and the patient succumbed to uraemia and superimposed infection. The anatomical diagnosis was retroperitoneal fibrosis.
Results
A summary of data on the miscible pool, daily turnover, and urinary excretion of uric acid in 16 patients with chronic renal disease is presented in Table 1 . The clearance rate of inulin ranged from 3 to 68 ml/min. Despite significant reduction in glomerular filtration the miscible pool of uric acid was only modestly raised, far less than that of other nitrogenous waste products.
Three patients with chronic lead nephropathy had plasma urate levels below 0 42 mmol/l while on a purine-free diet. On a regular diet plasma urate levels rose by 0 12 mmol/l. A similar rise in plasma urate with the addition of exogenous purines has been noted in patients with saturnine gout.14 The daily turnover of uric acid was normal in all patients except for the patient with sickle cell anaemia, who had a uric acid production of 5 46 mmol/day, a value which is about 40% higher than expected on the basis of his weight. An increased production of uric acid is not unexpected in a patient with chronic haemolytic anemia. The urinary excretion of uric acid ranged from 22*9 to 64*2 % of the uric acid produced, with a mean value of 35 -5 %. The cumulative urinary excretion of injected 14C-uric acid is shown in Fig. 1 for the first 13 subjects and in Figs. 2, 3 , and 4 for the remaining 3 patients. The urinary recovery of 14C-uric acid varied from 22 0 to 53 6 % of the administered dose, the average value being 32-0%.
This figure corresponds closely to the urinary uric acid as a percentage of the daily turnover, validating the calculation of the turnover rate of uric acid. In 9 healthy subjects urinary recovery of 14C-uric acid ranged from 63 0 to 75 * 5 % of the injected dose, the mean value being 6788%%.15 With the 2 tailed, nonpaired Student's t test the difference in urinary recovery of 14C-uric acid between the 2 groups is significant at a P value of <0 001.
In all but 2 of the 16 patients extrarenal excretion of uric acid was the major route of elimination. Studies on uric acid metabolism showed a mcdest increase in the miscible pool of uric acid, averaging about 50%. The production of uric acid was within the normal range, and thus renal failure does not affect extrarenal aspects of urate kinetics. All the patients studied had a decreased excretion of uric acid in the urine. The mean recovery of 14C-uric acid in the urine was 32-0%. whereas in healthy subjects we have found an average recovery of 67c8y% of injected 14C-uric acid in the urine. '5 The difference between the daily turnover of uric acid and the uric acid excreted in the urine in a 24-hour pericd represents that uric acid which has entered the gut in digestive juices. The recovery of 14C in uricolytic breakdown products emphasises the enhanced enteral uricolysis that occurs as a compensatory measure in chronic renal disease with compromised renal excretion of uric acid.
The distribution of 14C in various breakdown products indicates that carbon dioxide and ammonia are the principal degradation products of uric acid. Three patients in this study excreted 44, 54, and 71 % of injected 14C as carbon dioxide in expired air or in faeces. Almost all 14C in faeces has been shown to be incorporated into bacteria.9 In other words, the bacterial flora utilises carbon dioxide derived from uric acid as a result of uricolysis. Carbon dioxide and ammonia are likewise the major breakdown products in individuals who have no overt renal disease.17 Small amounts of 14C-uric acid was recovered in urinary allantoin (from 0 4 to 4 7%) and urinary urea (from 0 4 to 2 5%). Allantoic acid, another intermediary product in the breakdown of uric acid is inconsistently present in the urine. This compound is unstable, particularly at an acid pH, and spontaneously degrades to glyoxylic acid and urea.
Although increased extrarenal excretion of uric acid assumes the major role in urate homoeostasis as renal function deteriorates, some patients with azotaemia show a remarkable adaptation in their renal handling of uric acid. Renal functional studies revealed that 2 of our patients (cases 8 and 12) had urate/inulin clearance ratios of 1:3. The findings conform with the experience of Steele and Rieselbach18 that, with a reduction in glomerular filtration rate, there is a progressive increase in uric acid excretion per nephron. Their data show that residual nephrons of the chronically diseased kidney retain integrity of urate reabsorptive and secretory transport until inulin clearance has fallen to 15 ml/min. Further impairment of renal function is associated with a marked increase in the fractional excretion of filtered urate. On the other hand not all our patients had an enhanced excretion of uric acid by residual nephrons. Patients with chronic lead nephropathy, for example, had very low urate clearances in relation to their corresponding glomerular filtration rates. A similar finding has been reported by Emmerson.'4 With the elucidation of the mechanism of the acute attack of gout it is to be expected that this type of complication may occur during the course of renal disease of long duration. At present, when primary gout rarely leads to gouty nephropathy and primary renal disease is likely to be diagnosed at an early stage, the concomitant presentation of gout and azotaemia should lead the physician to consider that intrinsic renal disease may represent the underlying cause for hyperuricaemia. 
